Scarica l'app Stockscreener
1.19
4.03%
-0.05
Dopo l'orario di chiusura:
1.23
0.04
+3.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$1.24
Aprire:
$1.18
Volume 24 ore:
859.00K
Relative Volume:
0.73
Capitalizzazione di mercato:
$58.61M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-0.7169
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
-26.09%
1M Prestazione:
-28.74%
6M Prestazione:
-72.39%
1 anno Prestazione:
-92.76%
Intervallo 1D:
$1.14
$1.23
Intervallo di 1 settimana:
$1.14
$1.615
Portata 52W:
$1.14
$19.04
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.19 | 58.61M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from Guggenheim - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets Expectations - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets Estimates - MarketBeat
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN
Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (NASDAQ:CABA) Price Target Lowered to $7.00 at UBS Group - Defense World
Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com
Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com
UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener
Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks
Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada
Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com India
BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cabaletta Bio, Inc. SEC 10-K Report - TradingView
Cabaletta Bio Reports Clinical Wins in Multiple Diseases, Maintains Strong Cash Position - Stock Titan
Bank of New York Mellon Corp Sells 16,945 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline By Investing.com - Investing.com South Africa
Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline - Investing.com Australia
Are Value Hunters Buying Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat
Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire
Cabaletta Bio Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $22.71 - MarketBeat
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $22.71 - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN
Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com Australia
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):